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Supramolecular exo-functionalized palladium
cages: ﬂuorescent properties and biological
activity†
Andrea Schmidt,a,b Manuela Hollering,a Markus Drees,a Angela Casini*b and
Fritz E. Kühn*a
Metallosupramolecular systems are promising new tools for pharmaceutical applications. Thus, novel self-
assembled Pd(II) coordination cages were synthesized which were exo-functionalized with naphthalene
or anthracene groups with the aim to image their fate in cells. The cages were also investigated for their
anticancer properties in human lung and ovarian cancer cell lines in vitro. While the observed cytotoxic
eﬀects hold promise and the cages resulted to be more eﬀective than cisplatin in both cell lines, ﬂuo-
rescence emission properties were scarce. Therefore, using TD-DFT calculations, ﬂuorescence quenching
observed in the naphthalene-based system could be ascribed to a lower probability of a HOMO–LUMO
excitation and an emission wavelength outside the visible region. Overall, the reported Pd2L4 cages
provide new insights into the chemical–physical properties of this family of supramolecular coordination
complexes whose understanding is necessary to achieve their applications in various ﬁelds.
Introduction
Coordination-driven self-assembly is an ideal method for
constructing discrete, two- and three-dimensional metal-based
entities.1 These supramolecular coordination complexes
(SCCs) with well-defined geometries and cavities have found
applications not only in host–guest chemistry2 and catalytic
reactions,3 but also in biochemistry and medicine.4 For medic-
inal purposes, SCCs have been developed as drug delivery
vehicles,5–7 to recognize and interact with biomolecules8 and
to function as anticancer agents.9–11
Notably, Therrien et al. reported the first coordination cage,
a ruthenium–arene metallocage, used as a drug delivery
system for Pd and Pt acetylacetonato complexes, showing anti-
cancer eﬀects in cancer cell line A2780.6 In further studies,
ruthenium–arene metallocages displayed increased cytotoxic
eﬀects in human lung cancer cells compared to cisplatin, thus
acting as anticancer drugs per se.11 Interestingly, the first tox-
icity studies in vivo of SCCs as anticancer compounds were per-
formed with rhomboidal platinum(II) assemblies showing an
eﬀect on the reduction of the tumor growth rate in mice.10
A specific and attractive area of SCCs is the self-assembly of
M2L4 (M = metal, L = ligand) metallocages,
12 which can
enclose a variety of small molecules within their cavity, such
as ions13 and neutral molecules.14 In addition, the properties
of the M2L4 coordination cages can be optimized by
functionalization of the ligand framework.
Up to now, only a few reports on the biological properties of
Pd2L4 complexes have appeared.
5,15 Recently, we investigated
fluorescent palladium cages as drug delivery systems for cis-
platin, which proved to be active in cancer cells, while poorly toxic
ex vivo in healthy rat liver tissues.5 The obtained metallocages
showed fluorescence properties due to the used ligand system,
namely exo-functionalized bipyridyl ligands. However, upon
cage formation, a significant quenching of the ligands’ fluo-
rescence occurred due to the binding to Pd2+ ions. The extre-
mely low quantum yield of this first series of cages prevented
their study of cellular uptake via fluorescence microscopy in
most cases. Indeed, nearly all capsules and cages composed of
coordination metal–ligand bonds are non-emissive due to
quenching by the heavy transition metal ions.16 Only in a few
cases, highly fluorescent M2L4 cages were obtained.
17,18
However, fluorescent metal-based entities would be very
attractive in the medicinal inorganic chemistry field, to
achieve their imaging in biological environments via fluo-
rescence microscopy. In fact, an increasing number of reports
on anticancer metal compounds bearing fluorescent moieties
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for both therapeutic and imaging applications have
appeared.19 The reported metal-based compounds include
fluorescent Ru polypyridine complexes,20 as well as several
organometallic compounds among others.21
Therefore, in this work, in order to obtain cytotoxic metallo-
cages with improved fluorescence properties, we designed a
new series of self-assembled exo-functionalized Pd2L4 cages
coupled to fluorescent groups. The main structural motif of
the Pd2L4 cage compound 1 attached to naphthalene or
anthracene moieties is shown in Fig. 1. In addition, a cage fea-
turing a carboxy group in the exo-position was also included
for comparison purposes to better characterize the eﬀects of
the bulky fluorescent tags on the biological properties of
metallocages. Thus, the photophysical properties of cage com-
pounds and ligands were investigated and DFT calculations
were performed to rationalize the observed spectroscopic pro-
perties. In addition, the cages and respective ligands were
studied for their antiproliferative eﬀects in human cancer cell
lines in vitro.
Results and discussion
Synthesis and characterization
Rigid bidentate alkyne-based ligands 2a–2c attached to fluoro-
phores were synthesized in a two-step synthesis relying on
amide bond formation and a Sonogashira cross-coupling reac-
tion (Scheme 1). The dibromo derivatives 3a–3c were obtained
in yields ranging from 54 to 98% by treatment of the acid with
naphthyl- or anthracenyl-based amines in the presence of a
coupling reagent EDC and DMAP as a base. Compounds 3a–3c
were coupled with 3-ethynylpyridine using Sonogashira con-
ditions to give the ligands 2a–2c in 18 to 72% yield. In order to
evaluate the optical and biological properties of fluorophore-
based compounds compared to a non-fluorophore system,
carboxy-functionalized ligand 2d was prepared in 17% yield by
coupling 3,5-dibromobenzoic acid with 3-ethynylpyridine
using a Sonogashira reaction (Scheme 1).
The reaction of bidentate ligands 2a–2d and a palladium
precursor [Pd(NCCH3)4](BF4)2 in a 2 : 1 ligand :metal ratio in
DMSO at room temperature for 1 h yielded cage compounds
[Pd2(2)4](BF4)4 1a–1d in 63 to 81% (Scheme 2). Successful cage
formation was studied by 1H and DOSY NMR spectroscopy,
ESI mass spectrometry and single crystal X-ray diﬀraction.
The 1H NMR spectra of naphthalene-based ligand 2a,
carboxy-based ligand 2d and their corresponding cages 1a and
1d are exemplarily depicted in Fig. 2. Upon cage formation,
the pyridyl proton signals (Ha–Hd) experience a significant
downfield shift, especially the signals of Ha and Hb, which are
shifted by ca. 1 ppm. However, the proton signals of naphthal-
ene and anthracene moieties are not aﬀected by the coordi-
nation of the pyridyl group to palladium.
Diﬀusion-ordered NMR spectroscopy (DOSY) provides
additional evidence for the successful cage formation in solu-
tion (Table 1). 1H DOSY measurements of the cages 1a–d and
of the ligands 2a–d show diﬀusion coeﬃcients (D) in the range
of 0.81 to 0.90 × 10−10 m2 s−1 and 1.76 to 2.02 × 10−10 m2 s−1,
respectively, resulting in Dligand/Dcomplex ratios of about 2 : 1,
which are in accordance with the literature values.5,17 In
addition, DOSY NMR was used to estimate the size of the cage
compounds applying the Stokes–Einstein equation.22 The
hydrodynamic radii rs of the cage compounds were determined
to be between 1.2 and 1.4 nm.
Fig. 1 Schematic structure of Pd2L4 cage compound 1 attached to
ﬂuorophore moieties.
Scheme 1 Synthesis of ligands 2a–d via Sonogashira cross coupling.
Scheme 2 Synthesis of palladium(II) cages 1a–d via self-assembly using
bidentate ligands 2a–d and [Pd(NCCH3)4](BF4)2 as a precursor.
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The formation of Pd2L4 cages was further confirmed by
ESI-MS spectrometry showing isotopically resolved peaks of
[Pd2(2)4]
4+ and [Pd2(2)4BF4]
3+. For instance, the MS signals of
cage 1d at m/z 378.0 and 532.4 were assigned to the fragments
[1d – 4BF4
−]4+ and [1d – 3BF4
−]3+, respectively (Fig. 3).
Single-crystal X-ray diﬀraction provided structural verifica-
tion of cage 1b (Fig. 4). Suitable single crystals of 1b were
grown by vapor diﬀusion of diethyl ether into a DMF solution
of the cage. The crystal structure revealed the Pd2L4 cage con-
figuration in which the four bidentate ligands 2b are co-
ordinated to two Pd(II) ions in a square-planar fashion. The
cavity size is defined by the Pd⋯Pd distance of 11.9 Å and by
the distance between the two opposing pyridyl moieties of
10.5 Å. Based on spectroscopic evidence it can be assumed
that the solid-state structures of cages 1a, 1b, 1c and 1d are
similar.
The palladium cages 1a–d are stable for months under air
and light in both the solution and solid state. The cage com-
pounds are soluble in DMSO and DMF, as well as in mixtures
of DMF/acetone, DMSO/acetonitrile and DMSO/water, and not
soluble in less polar solvents. The cages are soluble in water
up to a concentration of 100 µM.
Optical properties and DFT calculations
As previously mentioned, the photophysical properties of
metallocages, particularly the emissive ones, are of special
interest to follow the uptake and distribution of cages in cells
by fluorescence microscopy. The absorption and emission
properties of our series are shown in Table 2 while the corres-
ponding spectra are depicted in Fig. 5 and 6. The excitation
spectra are shown in the ESI.†
The UV-Vis spectra of cages display strong ligand-based
absorption bands in the range of 260–350 nm deriving from
π–π* transitions of the highly conjugated ligands. The cages
Table 1 Comparison of diﬀusion coeﬃcients (D × 10−10 m2 s−1) of
ligands and palladium cages obtained by 1H DOSY NMR (400 MHz, [D6]
DMSO)
Cage D of cage Ligand D of ligand Ratio
1a 0.90 2a 2.02 2.25
1b 0.88 2b 1.76 2.00
1c 0.81 2c 1.77 2.19
1d 0.87 2d 2.02 2.32
Fig. 3 ESI mass spectrum of cage 1d (top), measured isotopic pattern
of the molecule signal [1d – 4BF4
−]4+ (middle) and calculated isotopic
distribution (bottom).
Fig. 4 Solid state molecular structure of 1b. Ellipsoids are shown at the
50% probability level. Hydrogen atoms, counterions and solvent mole-
cules are omitted for clarity. Selected bond lengths (Å) and angles (°):
Pd1–N1 2.013(3), Pd1–N2 2.031(3), Pd1⋯Pd1a 11.9308(6), N7⋯N7a
10.5029(6), N1–Pd1–N2 88.54(12), N2–Pd1–N3 92.45(12).
Fig. 2 Stacked 1H NMR spectra (400 MHz, [D6]DMSO) of ligand 2a (a),
cage 1a (b), ligand 2d (c) and cage 1d (d).
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exhibit a three- to four-times higher extinction coeﬃcient com-
pared to their respective ligands. As normally observed for this
type of cage compound, the carboxy-based ligand 2d (with a
quantum yield of 8%) presents a significant quenching of the
fluorescence upon cage formation, resulting in quantum
yields of 1% for 1d. However, in contrast to our expectations,
the fluorophore-based ligands and cages display fluorescence
quantum yields even lower, below 1%, and the anthracene-
based cage 1c exhibits no fluorescence at all.
In order to investigate the unexpected photophysical
properties of fluorophore-based systems, a time-dependent
density functional theory (TD-DFT) approach was used to cal-
culate the probability of the HOMO–LUMO excitation and the
emission wavelength. Also, the absorption and fluorescence
properties of the naphthalene-based ligand 2a (Φ < 1%) were
compared with those of the carboxy- and amine-based ligands
2d and 2e (Φ = 8 and 52%,5 respectively) (Fig. 7).
TD-single point calculations were performed to determine
the excitation probabilities of 2a, 2d and 2e (Table 3). Of inter-
est is the relevant excitation from HOMO to LUMO. Further
calculated transitions and the calculated UV-Vis spectra are
shown in the ESI.† Notably, the probability of a HOMO–LUMO
transition with 2% for ligand 2a is significantly lower than for
2d and 2e with 24 and 31%, respectively. The calculated prob-
ability is also in correlation with the quantum yield, as 2a is
the least and 2e the most fluorescent ligand.
To determine the wavelength of a possible fluorescence, the
energy diﬀerence between the energy after excitation and the
energy after relaxation (applying excited state geometry) was
calculated and transformed to a wavelength (Table 4). The
calculated emission wavelengths of 2d and 2e are 420 and
489 nm, respectively. In contrast the emission wavelength of
the naphthalene-based ligand 2a is calculated to be in the IR
region at 2000 nm.
Table 2 UV-Vis absorbance and ﬂuorescence emission properties of palladium cages and ligands
Compound εmax [L mol
−1 cm−1] λmax(abs) [nm] λ(ex) [nm] λmax(em) [nm] Φ
a [%]
1a 216 000 291, 311 330 370 0.3 ± 0.02
2a 68 100 290, 306 325 370 0.4 ± 0.03
1b 125 800 285, 325 350 405 0.1 ± 0.01
2b 36 700 287, 329 305 375, 450 0.2 ± 0.02
1c 256 800 291, 309, 381 330 — —
2c 73 700 290, 310 280 430 0.2 ± 0.01
1d 136 600 288, 310 280 355 1.2 ± 0.07
2d 40 000 288, 305 280 360 7.6 ± 0.31
aMean ± probable error of three measurements.
Fig. 5 Absorption spectra of cage compounds 1a and 1d, and ligands
2a and 2d in DMSO (c = 5 × 10−6 M and 10−5 M).
Fig. 6 Emission spectra of cage compounds 1a and 1d (λ(ex) = 330/
280 nm), and ligands 2a and 2d (λ(ex) = 325/280 nm) in DMSO
(c = 10−5 M).
Fig. 7 Structure of ligands 2a, 2d and 2e used for computational
studies.
Table 3 TD-DFT calculated absorption – HOMO→ LUMO transitions
Compound
λ(abs)
[nm] Probability
Origin
(MO)
Destination
(MO)
2a 360.27 0.0184 117 118
2d 346.06 0.2358 84 85
2e 359.87 0.3099 77 78
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According to the obtained results, the low fluorescence of
2a compared to 2d and 2e is attributable to two factors. First, a
HOMO–LUMO excitation is less likely for 2a than for the other
two compounds. Second, the energy diﬀerences between the
highest excited state and the non-relaxed ground state reveal
no emission of 2a in the visible region if emission arises
between these states. In contrast, 2d and 2e emit light in the
visible part, with the calculated wavelengths being slightly
longer than those of the absorbed photons.
Taking into consideration the geometry of the excited state
compared to the pure ground state, an explanation for the
emission properties of 2a can be proposed (Fig. 8). In the
ground state, the amide bond is almost planar with a dihedral
angle of 177° from the centered benzene ring to the naphthal-
ene substituent. However, in the excited state, this angle is
reduced to 99°, thus the amide bond is nearly orthogonal.
Therefore, the chromophoric system is disrupted leading to a
higher energy diﬀerence between the lowest point that can be
reached after fluorescence and the relaxed ground state.
Accordingly, a smaller amount of energy is converted into light
by emission resulting in a higher wavelength outside the
visible region.
Anticancer activity
The antiproliferative eﬀects of the coordination cages 1a–d,
the ligands 2a–d and the palladium precursor were evaluated
against the human cancer cell lines A549 (lung carcinoma)
and SKOV-3 (ovarian carcinoma) using the 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
The IC50 (inhibitory concentration to reduce viability to 50%)
values of the compounds are presented in Table 5 in compari-
son with cisplatin.
Overall, the fluorophore-based cages 1a–c are more toxic for
all tested cancer cells than cisplatin with the anthracenyl-
tagged 1c being the most cytotoxic, and the naphthyl-tagged
1a the least. The corresponding ligands alone elicit low to
moderate antiproliferative activities against the tested cancer
cells, with the exception of ligand 2b (IC50 ca. 3.8 μM). The
latter is the only ligand bearing a pyridyl moiety as the central
aromatic scaﬀold, which appears to induce a pronounced cyto-
toxic eﬀect compared to the benzyl moiety of ligand 2a. The
carboxy-based complex 1d, however, is less eﬀective in cell
lines A549 and SKOV-3 compared to cisplatin. Notably, the pal-
ladium precursor [Pd(NCCH3)4](BF4)2 and the bidentate ligand
2d are inactive (IC50 > 100 μM) for the selected cell lines. Based
on previous investigations,5 cage compound 1d can possibly
function as a drug delivery system for cisplatin due to its
encapsulation properties and its low cytotoxicity. The encapsu-
lation of cisplatin within cage 1d has been studied by 1H NMR
spectroscopy. The obtained spectrum (see Fig. S15†) shows
that the inward directed proton signals of the benzyl proton
He undergo significant downfield shifts upon encapsulation of
two equivalents of cisplatin, while broadening of the proton
signals takes place, in accordance with previous observations.5
Cage 1d encapsulating cisplatin (IC50 = 12.8 ± 1.2 μM) has
Table 5 Eﬀects of cages, ligands, Pd precursor and cisplatin on cell via-
bility in human lung carcinoma A549 and in human ovarian cancer cell
line SKOV-3 after 72 h incubation
Compound
IC50
a [μM]
A549 SKOV-3
Cage 1a 5.9 ± 1.4 8.0 ± 1.4
Ligand 2a 35.7 ± 5.9 46.6 ± 11.0
Cage 1b 1.4 ± 0.5 1.2 ± 0.7
Ligand 2b 3.8 ± 0.4 5.4 ± 2.1
Cage 1c 1.1 ± 0.3 1.1 ± 0.6
Ligand 2c 11.3 ± 0.8 23.6 ± 6.2
Cage 1d 82.6 ± 15.1 94.4 ± 7.9
Ligand 2d >100 >100
[(Cisplatin)2 ⊂ 1d] — 12.8 ± 1.2
[Pd(NCCH3)4](BF4)2 >100 >100
Cisplatin 8.9 ± 4.2 15.4 ± 2.2
aMean ± SD of at least three independent measurements.
Table 4 TD-DFT calculated emission – energy diﬀerence between the
non-relaxed excited state A (in ground state geometry) and the non-
relaxed ground state B (in optimized excited state geometry) and the
corresponding emission wavelength
Compound State A (a.u.) State B (a.u.) ΔE (eV) λ (em) [nm]
2a −1432.137122 −1432.159841 0.6181 2000
2d −1067.250746 −1067.358863 2.9420 420
2e −934.038722 −934.131580 2.5268 489
Fig. 8 Ground state of 2a (top) and the optimized ﬁrst excited state
after light absorption (bottom).
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slightly more potent anticancer activity than cisplatin alone in
SKOV-3. These preliminary results hold promise for the devel-
opment of new Pd2L4 cages as drug delivery systems.
Interestingly, the fluorophore-based ligands, especially 2b,
and the respective cages can act as anticancer drugs alone,
although their imaging in cancer cells via fluorescence
microscopy may not be possible in pharmacologically relevant
concentrations.
Conclusions
A series of exo-functionalized Pd2L4 coordination cages
coupled to fluorophore moieties has been prepared and
characterized including their photophysical properties. The
fluorophore-based compounds were compared with a carboxy-
functionalized system in terms of their emission properties
and anticancer activity in cancer cell lines. Interestingly, the
carboxy-based ligand exhibits a higher fluorescence quantum
yield than the ligands attached to fluorescent tags. The
quenching of the fluorescence in these systems can be
explained by TD-DFT calculations, showing a lower probability
for HOMO–LUMO transitions and emission in the IR region
(2000 nm). The cage compounds attached to fluorophore
groups display a higher cytotoxicity in all tested cancer cells
than cisplatin, making them suitable as anticancer agents. In
contrast, cage 1d has a very low anticancer activity with respect
to the cell lines A549 and SKOV-3, which may still make it suit-
able as a non-toxic drug delivery system for cisplatin or other
drugs, and ongoing studies in our group are exploring this
possibility. As a matter of fact preliminary cytotoxicity data on
the [(cisplatin)2 ⊂ 1d] system reinforce the relevance of our
strategy. Other fluorophore-based ligands and corresponding
metallocages are currently under investigation in our labora-
tories, where the length of the linker between the bipyridyl
ligands and the fluorescent tags is increased to avoid the pre-
dicted torsion of the amide bond angle in the excited state.
Finally, it should be pointed out that still the mechanisms of
anticancer action of metallocages have not yet been clarified in
most cases, although a few studies suggest diﬀerent modes of
action with respect to cisplatin, for instance palladium heli-
cates induce the disruption of the cell membrane.15a
Experimental
General remarks
All reagents were purchased from commercial sources and
used without further purification. Chromatographic separ-
ations were performed using silica gel (60–200 µm). NMR
spectra were recorded with a Bruker Avance DPX 400 or a
Bruker Avance III 400 or a Bruker Avance I 500 spectrometer at
a temperature of 298 K. The spectra were referenced to the
residual 1H and 13C{1H} signals of the solvents in parts per
million (ppm). Abbreviations for NMR multiplicities are:
singlet (s), doublet (d), triplet (t), multiplet (m). Coupling
constants J are given in Hz. The IR spectra were collected on a
Varian ATR-FTIR instrument. Electrospray ionization (ESI) and
fast atomic bombardment (FAB) mass spectra were obtained
on a Thermo Scientific LCQ/Fleet spectrometer and a Finnigan
MAT spectrometer, respectively. UV-Vis absorption spectra
were acquired with a Jasco V-550 UV-Vis spectrometer.
General procedure for the synthesis of dibromo derivatives
Acid (1.0 equiv.), amine (1.0 equiv.), N-(3-dimethyl-
aminopropyl)-N′-ethylcarbodiimide hydrochloride (1.2 equiv.)
and 4-dimethylaminopyridine (10 mol%) were dissolved in dry
dichloromethane and stirred under an argon atmosphere at
room temperature for 2 h. To the reaction mixture, 2 M HCl
(40 mL) was added and the aqueous phase was extracted three
times with dichloromethane (40 mL). The organic phase was
dried over MgSO4 and concentrated under reduced pressure.
The crude product was recrystallized in dichloromethane to
yield dibromide as a solid.
3,5-Dibromo-N-(naphthalen-1-yl)benzamide 3a. A mixture of
3,5-dibromobenzoic acid (280 mg, 1.00 mmol), 1-naphthyl-
amine (143 mg, 1.00 mmol), EDC (230 mg, 1.20 mmol) and
DMAP (12.2 mg, 0.10 mmol) in dichloromethane (15 mL)
yielded 3a (218 mg, 0.54 mmol, 54%) as a white solid. 1H NMR
(400 MHz, [D6]DMSO): δ [ppm] = 10.63 (s, 1 H, NH), 8.26 (d,
J = 1.6 Hz, 2 H, Hb), 8.14 (t, J = 1.7 Hz, 1 H, Ha), 8.01–7.97 (m,
2 H, Hnaph), 7.89 (d, J = 7.8 Hz, 1 H, Hnaph), 7.60–7.54 (m, 4 H,
Hnaph).
13C NMR (101 MHz, [D6]DMSO): δ [ppm] = 163.4,
138.0, 136.3, 133.8, 133.3, 129.8, 129.0, 128.1, 126.7, 126.2,
126.1, 125.5, 123.9, 123.4, 122.7. IR (solid): ν [cm−1] = 3442,
2840, 1637, 1521, 1346, 1280, 863, 773, 734, 665, 557, 485. MS
(ESI, MeCN): m/z = 405.99 [M + H]+ (calcd for C17H12Br2NO:
405.93).
2,6-Dibromo-N-(naphthalen-1-yl)isonicotinamide 3b. A
mixture of 2,6-dibromopyridine-4-carboxylic acid (562 mg,
2.00 mmol), 1-naphthylamine (286 mg, 2.00 mmol), EDC
(460 mg, 2.40 mmol) and DMAP (24.4 mg, 0.20 mmol) in
dichloromethane (20 mL) yielded 3b (798 mg, 1.97 mmol,
98%) as a purple solid. 1H NMR (400 MHz, [D6]DMSO): δ
[ppm] = 10.81 (s, 1 H, NH), 8.27 (s, 2 H, Ha), 8.06–7.98 (m, 2 H,
Hnaph), 7.90 (d, J = 8.1 Hz, 1 H, Hnaph), 7.64–7.55 (m, 4 H,
Hnaph).
13C NMR (101 MHz, [D6]DMSO): δ [ppm] = 162.0,
147.0, 140.6, 134.2, 133.7, 132.6, 128.7, 128.1, 126.9, 126.3,
126.2, 125.9, 125.5, 123.7, 123.3. IR (solid): ν [cm−1] = 3442,
2915, 1641, 1519, 1351, 1297, 1155, 873, 775, 694, 611, 555,
491. MS (FAB): m/z = 406.5 [M + H]+ (calcd for C16H11Br2N2O:
406.9).
N-(Anthracen-2-yl)-3,5-dibromobenzamide 3c. A mixture of
3,5-dibromobenzoic acid (280 mg, 1.00 mmol), 2-aminoanthra-
cene (193 mg, 1.00 mmol), EDC (230 mg, 1.20 mmol) and
DMAP (12.2 mg, 0.10 mmol) in dichloromethane (20 mL)
yielded 3a (415 mg, 0.91 mmol, 91%) as a green solid. 1H NMR
(400 MHz, [D6]DMSO): δ [ppm] = 10.67 (s, 1 H, NH), 8.63 (s,
1 H, Hanth), 8.53 (d, J = 6.4 Hz, 2 H, Hanth), 8.22 (d, J = 1.7 Hz,
2 H, Hb), 8.13–8.06 (m, 4 H, Ha, Hanth), 7.79 (dd, J = 1.9,
9.1 Hz, 1 H, Hanth), 7.53–7.46 (m, 2 H, Hanth).
13C NMR
(101 MHz, [D6]DMSO): δ [ppm] = 162.9, 138.4, 136.3, 135.7,
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131.7, 131.4, 130.7, 129.8, 128.8, 128.7, 128.1, 127.8, 125.9,
125.7, 125.4, 125.2, 122.7, 121.6, 115.8. IR (solid): ν [cm−1] =
3770, 2915, 1639, 1511, 1309, 1257, 1097, 887, 734, 663, 605,
474. MS (FAB): m/z = 279.8 [M − anthracene + 2H]2+ (calcd
for C7H6Br2NO: 279.9), 297.2 [M − 2Br + 2H]2+ (calcd for
C21H15NO: 297.1).
General procedure for the synthesis of ligands
Dibromide (1.0 equiv.), 3-ethynylpyridine (4.0 equiv.),
[Pd(PPh3)2Cl2] (10 mol%) and CuI (10 mol%) were added to
degassed triethylamine and heated under an argon atmo-
sphere at 70 °C. After 72 hours, the reaction mixture was
diluted with ethyl acetate (50 mL) and filtered over celite. The
solvent was removed under reduced pressure and the crude
residue was further purified by column chromatography
(CH2Cl2 : MeOH = 100 : 5) to give the ligand as a solid.
Ligand 2a. A mixture of dibromide 3a (182 mg, 0.45 mmol),
3-ethynylpyridine (186 mg, 1.80 mmol), [Pd(PPh3)2Cl2]
(31.6 mg, 0.05 mmol) and CuI (8.60 mg, 0.05 mmol) in tri-
ethylamine (10 mL) yielded 2a (135 mg, 0.30 mmol, 67%) as a
light yellow solid. 1H NMR (400 MHz, [D6]DMSO): δ [ppm] =
10.68 (s, 1 H, NH), 8.84 (s, 2 H, Ha), 8.64 (d, J = 4.4 Hz, 2 H,
Hb), 8.34 (s, 2 H, Hf), 8.07–7.98 (m, 5 H, He, Hd, Hnaph), 7.90
(d, J = 8.0 Hz, 1 H, Hnaph), 7.64–7.56 (m, 4 H, Hnaph), 7.52 (dd,
J = 7.8, 5.0 Hz, 2 H, Hc). DOSY NMR (400 MHz, [D6]DMSO):
D [m2 s−1] = 2.02 × 10−10. 13C NMR (101 MHz, [D6]DMSO):
δ [ppm] = 164.5, 151.8, 149.5, 138.8, 136.7, 135.8, 133.8, 133.5,
131.2, 129.1, 128.1, 126.6, 126.2, 126.1, 125.6, 124.0, 123.8,
123.4, 122.9, 118.9, 90.6, 87.8. IR (solid): ν [cm−1] = 3467, 3181,
2873, 1639, 1521, 1268, 1020, 892, 792, 700, 626, 539. MS (ESI,
MeCN/DMSO): m/z = 450.31 [M + H]+ (calcd for C31H20N3O:
450.16).
Ligand 2b. A mixture of dibromide 3b (183 mg, 0.45 mmol),
3-ethynylpyridine (186 mg, 1.80 mmol), [Pd(PPh3)2Cl2]
(31.6 mg, 0.05 mmol) and CuI (8.60 mg, 0.05 mmol) in tri-
ethylamine (10 mL) yielded 2b (146 mg, 0.32 mmol, 72%) as a
yellow solid. 1H NMR (400 MHz, [D6]DMSO): δ [ppm] = 10.87
(s, 1 H, NH), 8.90 (s, 2 H, Ha), 8.68 (d, J = 4.1 Hz, 2 H, Hb), 8.33
(s, 2 H, He), 8.13 (d, J = 7.9 Hz, 2 H, Hd), 8.09–7.99 (m, 2 H,
Hnaph), 7.92 (d, J = 8.0 Hz, 1 H, Hnaph), 7.67–7.53 (m, 6 H, Hc,
Hnaph). DOSY NMR (400 MHz, [D6]DMSO): D [m
2 s−1] = 1.76 ×
10−10. 13C NMR (101 MHz, [D6]DMSO): δ [ppm] = 163.3, 152.1,
150.1, 143.3, 143.1, 139.3, 133.8, 133.0, 128.9, 128.2, 126.9,
126.3, 126.2, 125.6, 125.4, 123.9, 123.4, 118.2, 90.7, 86.8. IR
(solid): ν [cm−1] = 3052, 2915, 1673, 1533, 1407, 1268, 1022,
763, 698, 624, 495. MS (ESI, MeCN/DMSO): m/z = 451.38
[M + H]+ (calcd for C30H19N4O: 451.16).
Ligand 2c. A mixture of dibromide 3c (130 mg, 0.29 mmol),
3-ethynylpyridine (118 mg, 1.16 mmol), [Pd(PPh3)2Cl2]
(20.0 mg, 0.03 mmol) and CuI (5.50 mg, 0.03 mmol) in tri-
ethylamine (10 mL) yielded 2c (26.7 mg, 0.05 mmol, 18%) as a
light brown solid. 1H NMR (400 MHz, [D6]DMSO): δ [ppm] =
10.73 (s, 1 H, NH), 8.84 (s, 2 H, Ha), 8.67–8.65 (m, 3 H, Hb,
Hanth), 8.54–8.53 (m, 2 H, Hanth), 8.28 (s, 2 H, Hf), 8.13–8.06
(m, 6 H, Hd, He, Hanth), 7.85–7.82 (m, 1 H, Hanth), 7.53–7.47
(m, 4 H, Hc, Hanth). DOSY NMR (400 MHz, [D6]DMSO):
D [m2 s−1] = 1.77 × 10−10. 13C NMR (101 MHz, [D6]DMSO): δ
[ppm] = 164.4, 151.6, 149.4, 144.5, 139.3, 134.8, 134.5, 134.2,
133.3, 131.3, 128.9, 128.7, 128.5, 128.2, 127.9, 126.9, 126.8,
126.0, 125.9, 125.0, 124.1, 123.0, 119.1, 117.3, 90.7, 87.9. IR
(solid): ν [cm−1] = 3282, 3085, 2956, 1643, 1477, 1284, 1020,
885, 802, 742, 700, 626, 470. MS (ESI, MeCN/DMSO): m/z =
500.34 [M + H]+ (calcd for C35H22N3O: 500.18).
Ligand 2d. A mixture of 3,5-dibromobenzoic acid (271 mg,
0.97 mmol), 3-ethynylpyridine (400 mg, 3.88 mmol),
[Pd(PPh3)2Cl2] (68.1 mg, 0.10 mmol) and CuI (18.5 mg,
0.10 mmol) in triethylamine (15 mL) yielded 2d (54.2 mg,
0.17 mmol, 17%) as a white solid after recrystallization in
dichloromethane. 1H NMR (400 MHz, [D6]DMSO): δ [ppm] =
8.82 (d, J = 1.9 Hz, 2 H, Ha), 8.63 (dd, J = 1.7, 4.9 Hz, 2 H, Hb),
8.12 (d, J = 1.6 Hz, 2 H, Hf), 8.08–8.01 (m, 3 H, Hd, He), 7.50
(dd, J = 4.8, 7.6 Hz, 2 H, Hc). DOSY NMR (400 MHz, [D6]
DMSO): D [m2 s−1] = 2.02 × 10−10. 13C NMR (101 MHz, [D6]
DMSO): δ [ppm] = 165.8, 151.9, 149.5, 138.9, 137.6, 132.4,
123.8, 123.0, 118.9, 90.3, 87.9. IR (solid): ν [cm−1] = 3519, 2827,
1589, 1261, 1164, 1043, 800, 692, 642, 457. MS (ESI, MeCN/
DMSO): m/z = 325.31 [M + H]+ (calcd for C21H13N2O2: 325.10).
General procedure for the synthesis of cages
A solution of [Pd(NCCH3)4](BF4)2 (2.0 equiv.) and ligand
(4.0 equiv.) in DMSO was stirred at RT for one hour. After pre-
cipitation by addition of acetone and diethyl ether, the solid
was filtered and washed with acetone and diethyl ether to yield
the cage compound as a solid.
Cage 1a. [Pd(NCCH3)4](BF4)2 (22.2 mg, 0.05 mmol) and 2a
(45.0 mg, 0.10 mmol) in DMSO (2 mL) gave 1a (44.7 mg,
0.02 mmol, 76%) as a light brown solid. 1H NMR (400 MHz,
[D6]DMSO): δ [ppm] = 10.72 (s, 1 H, NH), 9.67 (s, 2 H, Ha), 9.45
(d, J = 5.8 Hz, 2 H, Hb), 8.45 (d, J = 1.5 Hz, 2 H, Hf), 8.35 (d, J =
8.0 Hz, 2 H, Hd), 8.21 (s, 1 H, He), 8.00–7.96 (m, 2 H, Hnaph),
7.91–7.86 (m, 3 H, Hc, Hnaph), 7.57–7.52 (m, 4 H, Hnaph). DOSY
NMR (400 MHz, [D6]DMSO): D [m
2 s−1] = 8.97 × 10−11.
13C NMR (101 MHz, [D6]DMSO): δ [ppm] = 164.1, 153.0, 150.9,
143.1, 136.4, 136.2, 133.8, 133.3, 132.5, 129.0, 128.2, 127.5,
126.8, 126.2, 126.1, 125.6, 124.0, 123.3, 122.2, 122.1, 93.3, 86.0.
11B NMR (128 MHz, [D6]DMSO): δ [ppm] = −1.07. 19F NMR
(377 MHz, [D6]DMSO): δ [ppm] = −147.78 (10BF4−), −147.83
(11BF4
−). MS (ESI, DMSO/MeCN): m/z = 502.81 [M − 4BF4−]4+
(calcd for Pd2C124H76N12O4: 502.86), 699.58 [M − 3BF4−]3+
(calcd for Pd2C124H76N12O4BF4: 699.48).
Cage 1b. [Pd(NCCH3)4](BF4)2 (22.2 mg, 0.05 mmol) and 2b
(45.1 mg, 0.10 mmol) in DMSO (2 mL) gave 1b (47.8 mg,
0.02 mmol, 81%) as a light brown solid. 1H NMR (400 MHz,
[D6]DMSO): δ [ppm] = 10.89 (s, 1 H, NH), 9.66 (s, 2 H, Ha), 9.44
(d, J = 5.7 Hz, 2 H, Hb), 8.42–8.40 (m, 4 H, He, Hd), 8.01–7.88
(m, 5 H, Hc, Hnaph), 7.59–7.53 (m, 4 H, Hnaph). DOSY NMR
(400 MHz, [D6]DMSO): D [m
2 s−1] = 8.80 × 10−11. 13C NMR
(101 MHz, [D6]DMSO): δ [ppm] = 162.9, 153.6, 151.3, 143.6,
143.4, 142.6, 133.8, 132.8, 130.6, 128.8, 127.5, 126.6, 126.3,
126.2, 125.6, 123.9, 123.2, 121.5, 93.1, 84.6. 11B NMR
(128 MHz, [D6]DMSO): δ [ppm] = −1.28. 19F NMR (377 MHz,
[D6]DMSO): δ [ppm] = −148.13 (10BF4−), −148.19 (11BF4−). MS
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(ESI, DMSO/MeCN): m/z = 503.52 [M − 4BF4−]4+ (calcd for
Pd2C120H72N16O4: 503.85), 700.17 [M − 3BF4−]3+ (calcd for
Pd2C120H72N16O4BF4: 700.80).
Cage 1c. [Pd(NCCH3)4](BF4)2 (13.3 mg, 0.03 mmol) and 2c
(30.0 mg, 0.06 mmol) in DMSO (2 mL) gave 1c (24.1 mg,
0.01 mmol, 63%) as a green solid. 1H NMR (400 MHz, [D6]
DMSO): δ [ppm] = 10.75 (s, 1 H, NH), 9.66 (s, 2 H, Ha), 9.48 (d,
J = 5.9 Hz, 2 H, Hb), 8.63–8.59 (m, 1 H, Hanth), 8.54–8.48 (m,
2 H, Hanth), 8.39–8.28 (m, 4 H, Hf, Hd), 8.09–8.02 (m, 4 H, He,
Hanth), 7.92–7.86 (m, 2 H, Hc), 7.77 (d, J = 9.4 Hz, 1 H, Hanth),
7.52–7.46 (m, 2 H, Hanth). DOSY NMR (400 MHz, [D6]DMSO): D
[m2 s−1] = 8.05 × 10−11. 11B NMR (128 MHz, [D6]DMSO): δ
[ppm] = −1.30. 19F NMR (377 MHz, [D6]DMSO): δ [ppm] =
−148.13 (10BF4−), −148.19 (11BF4−). MS (ESI, DMSO/MeCN):
m/z = 552.43 [M − 4BF4−]4+ (calcd for Pd2C140H84N12O4:
552.87). Note: this complex is too insoluble to obtain a
13C NMR spectrum.
Cage 1d. [Pd(NCCH3)4](BF4)2 (22.2 mg, 0.05 mmol) and 2d
(32.4 mg, 0.10 mmol) in DMSO (2 mL) gave 1d (35.4 mg,
0.02 mmol, 76%). 1H NMR (400 MHz, [D6]DMSO): δ [ppm] = 9.67
(s, 2 H, Ha), 9.38 (d, J = 5.7 Hz, 2 H, Hb), 8.35 (d, J = 7.8 Hz, 2 H,
Hd), 8.21 (s, 2 H, Hf) 8.10 (s, 1 H, He), 7.85 (dd, J = 5.8, 7.8 Hz,
2 H, Hc). DOSY NMR (400 MHz, [D6]DMSO): D [m
2 s−1] = 8.71 ×
10−11. 11B NMR (128 MHz, [D6]DMSO): δ [ppm] = −1.22. MS
(ESI, DMSO/MeCN): m/z = 377.96 [M − 4BF4−]4+ (calcd for
Pd2C84H48N8O8: 377.54), 532.42 [M − 3BF4−]3+ (calcd for
Pd2C84H48N8O8BF4: 532.39). Note: this complex is too insoluble
to obtain a 13C NMR spectrum.
Crystallographic details
For detailed information see the ESI.† Crystallographic Data
(excluding structure factors) for the structure reported in this
paper has been deposited with the Cambridge Crystallographic
Data Centre as supplementary publication no. CCDC
1454096 (1b).
Fluorescence spectroscopy and determination of quantum
yield
The emission spectra were recorded on a Varian Cary Eclipse
fluorescence spectrophotometer. For each compound,
dilutions in DMSO at a concentration of 10 μM were prepared.
First, UV-Vis spectra of compounds were recorded in DMSO, to
determine the wavelength of the absorbance maximum. The
absorbance maximum should be between 0.3 and 1. The
measured absorbance wavelength was used as the excitation
wavelength for fluorescence microscopy.
For the determination of quantum yields,23,24 the choice of
the right quantum standard is important. Depending on the
excitation and emission wavelengths of the compounds,
quinine sulfate or naphthalene was used as a standard.
Diﬀerent dilutions of the compounds and standards were pre-
pared in DMSO and sulfuric acid or cyclohexane, respectively.
Absorbance spectra were recorded using three diﬀerent con-
centrated solutions, not exceeding an absorbance of 0.1 to
minimize reabsorption eﬀects. The same solutions were used
for recording the fluorescence spectra. The excitation wave-
length should be the same for the compound and standard. In
addition, all fluorescence spectra must be recorded with
constant excitation and emission slits. The quantum yield of a
compound was calculated using the Stokes Einstein
equation.24
Computational details
All calculations have been carried out by using the GAUSSIAN
09 D.01 package.25 The hybrid functional B3LYP26,27 has been
chosen together with the basis set 6-31+G*.28–30 For the excited
states optimization, a time-dependent DFT formalism31,32 has
been applied using the B3LYP functional. All calculations have
been performed in solution with PCM as an implicit solvation
model and DMSO as a solvent.
Cell viability assay (MTT assay)
Human lung cancer cell line A549 and human ovarian cancer
cell line SKOV-3 were obtained from the European Centre of
Cell Cultures (ECACC, Salisbury, UK) and maintained in
culture as described by the provider. The cells were cultured in
DMEM (Dulbecco’s Modified Eagle Medium) containing 10%
fetal bovine serum (FBS) and 1% penicillin/streptomycin at
37 °C and 5% CO2. For evaluation of growth inhibition, cells
were seeded in 96-well plates at a concentration of 11 000 cells
per well and grown for 24 h in complete medium. Solutions of
the compounds with the required concentration (0.5 to
150 μM) were prepared by diluting a freshly prepared stock
solution (10−2 M in DMSO) of the corresponding compound in
aqueous DMEM medium. 200 μL of the dilutions were added
to each well and the cells were incubated for 72 h. Following
drug exposure, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) was added to the cells at a final concen-
tration of 0.5 mg mL−1 and incubated for 2 h. Afterwards the
culture medium was removed and violet formazan was dis-
solved in DMSO. The optical density was quantified in tetra-
plicates at 550 nm using a multi-well plate reader. The
percentage of surviving cells was calculated from the ratio of
absorbance of treated to untreated cells. The IC50 values were
calculated as inhibitory concentration of cell growth at 50%
by plotting the percentage of surviving cells against the drug
concentration and presented as mean ± SE of at least three
independent experiments.
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